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Abstract
Background: By definition, effect of synonymous single-nucleotide variants (SNVs) on protein folding and function
are neutral, as they alter the codon and not the encoded amino acid. Recent examples indicate tissue-specific and
transfer RNA (tRNA)-dependent effects of some genetic variations arguing against neutrality of synonymous SNVs
for protein biogenesis.
Results: We performed systematic analysis of tRNA abunandance across in various models used in cystic fibrosis
(CF) research and drug development, including Fischer rat thyroid (FRT) cells, patient-derived primary human
bronchial epithelia (HBE) from lung biopsies, primary human nasal epithelia (HNE) from nasal curettage, intestinal
organoids, and airway progenitor-directed differentiation of human induced pluripotent stem cells (iPSCs). These
were compared to an immortalized CF bronchial cell model (CFBE41o−) and two widely used laboratory cell lines,
HeLa and HEK293. We discovered that specific synonymous SNVs exhibited differential effects which correlated with
variable concentrations of cognate tRNAs.
Conclusions: Our results highlight ways in which the presence of synonymous SNVs may alter local kinetics of
mRNA translation; and thus, impact protein biogenesis and function. This effect is likely to influence results from
mechansistic analysis and/or drug screeining efforts, and establishes importance of cereful model system selection
based on genetic variation profile.
Keywords: Nucleotide variants, Synonymous single nucleotide polymorphisms, tRNA, Protein translation, Cystic
fibrosis
Background
Genetic variations are the source of evolutionary diversity
and are grouped into three general categories: deleterious,
neutral and beneficial. Fitness landscapes, both at single-
protein and whole-organism levels, are generally used to
depict phenotypic manifestation of genotypes [1–3]. Pre-
dictive selection of variants with physiological effect is
limited by the paucity of the quantitative systematic ana-
lysis of cellular contributors to variation in both tissues
and cell lines. However, systematic assessment of the ef-
fect of genetic variations on the whole proteome level is
laborious, and only a small set of proteins has been exten-
sively examined to date (predominantly addressing effects
of single nucleotide variants, SNVs) [4–9]. The outcome
of a genetic change largely depends on overall genetic
background [1, 10]. Interactions between genes and epi-
static effects of intra- or inter-genic variations [11–20],
together with quantitative differences in the components
of central cellular processes (e.g. transcription, translation)
contribute substantially to phenotypic heterogeneity. Fur-
thermore, recent examples suggest that tissue-specific ef-
fects of certain forms of genetic variation are linked to
components that comprise cellular translation machinery
[21–23].
Translation is a central process at the crossroads be-
tween genome and proteome. Large proportions of
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cellular resources are dedicated to this essential function:
35–45% of the genome is assigned to proteins of the
translation apparatus, and ~ 30–50% of energy produc-
tion with the cell is consumed by translation machinery
[24]. Transfer RNAs (tRNAs) convert the nucleotide
chemistry (mRNA) into a peptide alphabet (protein).
‘Ready-to-translate’ tRNA repertoires can adapt accord-
ing to cellular physiology and are controlled by several
transcriptional and posttranscriptional regulatory pro-
cesses [25–27]. tRNAs have co-evolved to serve the de-
generate DNA code, and many synonymous codons have
a specific tRNA isoacceptor (i.e., a distinct tRNA carry-
ing the same amino acid but with variation in the anti-
codon and tRNA body sequence). On the other hand,
through modifications in the anticodon, some isoaccep-
tors serve more than one synonymous codon. Cellular
concentrations of tRNA isoacceptors vary greatly and
shape behavior of synonymous codons, which in turn,
has a profound effect on translation kinetics and accur-
acy (Fig. 1), as well as protein expression level, folding
and activity [25–27]. Emerging knowledge regarding the
ways tRNAs read synonymous codons has altered the
view of synonymous SNVs, which have been historically
considered inconsequential for protein folding and func-
tion as they change the codon but not the encoded
amino acid. For example, a major determinant of elong-
ation speed for a codon is the concentration of its cog-
nate tRNA [28] and the ratio of cognate to near-cognate
tRNA [29]. As a corollary of this view, the effect of syn-
onymous SNVs on translation kinetics can be estimated
from tRNA abundance. Here, we perform systematic
global quantification of the tRNAomes within various
human cell lines and model systems used in the study of
cystic fibrosis (CF), and frame the effect of synonymous
SNVs (sSNVs) in the context of cellular translation re-
sources that directly link a particular SNV to cellular
physiology (e.g. protein function). Rationale for working
with CF cell models stems from the fact that the gene
responsible for this disease – the cystic fibrosis trans-
membrane conductance regulator (CFTR) – encodes an
abundance of well-classified SNVs (https://cftr2.org/)
and synonymous nucleotide polymorphisms (SNPs,
defined as SNVs with prevalence higher than 1% in the
population [30]). Furthermore, theratype of disease-
causing mutations in CFTR, along with other effects of
newly developed modulator compounds, can be mark-
edly non-uniform in different cell lines and disease
models. Although tRNAs exhibit a similar global pattern
of abundance among the tested models, specific isoac-
ceptors oppose this trend; i.e., synonymous SNVs at
CFTR codons read by those tRNAs would result in sig-
nificant variation in different models. This interpretation
is not restricted to CFTR and should also be useful for
more global predictions regarding genotype-phenotype
consequences attributable to synonymous SNVs.
Results
Rationale for model choice in tRNAome comparisons
CFTR functions as an epithelial anion channel and
resides in the apical membranes of multiple tissues, in-
cluding airways, hepatic and pancreatic ducts, as well
as pancreatic acini and sweat ducts. In addition to the
most prevalent cause of disease – deletion of three nu-
cleotides (F508del) – more than 2000 CF-associated
variants and SNPs have been identified in CFTR, which
may impact both clinical severity and penetrance [31].
The FDA recently approved treatment of F508del-
CFTR homozygous patients with combination drugs
such as Orkambi™ and Symdeko™, which contain both a
CFTR ion channel gating potentiator, ivacaftor (VX-
770), and protein misfolding corrector compound,
lumacaftor (VX-809) or tezacaftor (VX-661). Clinical
testing of these agents has revealed considerable het-
erogeneity in patient response [32] that may reflect a
number of factors, including influence of intragenic
modifiers or specific differences in abundance of factors
that govern drug effectiveness within cells and tissues.
The number of compounds that influence specific
CFTR mutations are rapidly increasing and may exhibit
significant differences in effect depending on the model
system being tested [33]. Our earlier studies of a syn-
onymous SNP in CFTR (c.2562 T > G) revealed strong
tissue-specific effects due to differences within tRNA
households among distinct human tissues [22]. Thus,
we hypothesized that variations in tRNA sets may alter
CFTR translation profiles, and consequently, the effect
of synonymous SNVs/SNPs in each system.
Fig. 1 General model of mRNA translation. The rate of translation for
each codon depends on the collision of tRNAs with the ribosome
(gray) and is proportional to cellular concentration of the cognate
tRNA isoacceptor [75]. Codons pairing to low-abundance tRNAs
(blue) exhibit slower velocity than codons pairing to high-abundance
tRNAs (red), which are translated more rapidly
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We determined tRNAomes from two CF patient-
derived primary human bronchial epithelia (HBE) sam-
ples harvested at the time of lung biopsy and compared
these to various models used in CF research for CFTR
mechanistic analysis and/or drug screening. These
model systems included intestinal organoids, Fischer rat
thyroid (FRT) epithelia, an immortalized CF bronchial
cell line (CFBE41o−), human nasal epithelia (HNE) from
rhinal scrapings, and airway progenitor cells directed to-
wards differentiation from human induced pluripotent
stem cells (iPSCs). We also evaluated tRNAomes from
two laboratory cell lines, HeLa and HEK293, which are
commonly used in CF research for addressing molecular
features of CFTR mutations during protein biogenesis.
The selection of these model systems was based on
discussions resulting from an international Cystic Fibro-
sis Foundation workshop centered on CFTR theratyping
with applications to both common and rare CFTR vari-
ants [34]. Patient-derived rectal organoids have become
increasingly utilized for CF diagnostics, high-throughput
drug screening (in 384-well format), patient-specific re-
sponsiveness/personalized theratyping, and testing FDA/
EMA-approved drugs (e.g. Orkambi™) for effect(s) on
rare CF mutations [34–36]. FRT cells have been exten-
sively used in compound library screens by Vertex Phar-
maceuticals, leading to discovery of clinically approved
CFTR modulators such as ivacaftor, lumacaftor, tezacaf-
tor, and a series of next-generation agents. Theratype
protocols in the FRT model have been recognized by the
FDA as potentially relevant to drug label expansion for
individuals with unusual, ultra-rare, or even private
SNVs in CFTR. Primary HNE cells are particularly useful
for optimizing modulator choices among individual CF
subjects with forms of the disease less suitable for defini-
tive Phase III clinical trials [37]. The developments of
new techniques to derive functional airway cell models
from iPSCs using CF-patients’ somatic cells holds prom-
ise for in vitro modeling of CFTR theratype analysis,
drug screening, and future cell-based regenerative ther-
apies [38–40]. In the present study, we therefore tested
iPSCs at: (1) day 0, following fibroblast depletion and at
primitive streak induction, (2) day 5 upon dissociation of
embryoid bodies, (3) day 15, upon lung progenitor in-
duction, and (5) day 21, as expanded lung progenitors
[41, 42]. We also included the CFBE41o− cell line for
comparison, since this model represents one of the most
widely used immortalized cell models in basic CF re-
search [43].
Global tRNA abundance pattern is similar among models
but differs for a specific population of codons
tRNAome profiles were obtained for each model system
using tRNA-tailored microarrays [44] with 40 tDNA
probes covering the full-length sequence of 49 nuclear-
encoded cytoplasmic tRNAs as described previously [44,
45]. tRNA isoacceptors with a sequence difference of
more than 8 nucleotides can be unambiguously deter-
mined in this fashion [46]. For example, specific isoac-
ceptors pairing to proline codons cannot be
unambiguously distinguished because they have fewer
than 8 nt difference; while for other codons (e.g. AAA),
more than one tRNA with variations in sequence encod-
ing the tRNA body is detectable (Fig. 2). Notably, arrays
showed a strong reproducibility between biological repli-
cates (Additional file 1 Figure S1a-e). Distribution of
overall tRNA abundancies was similar among the
models – e.g. acceptors reading GAU/C (Asp) and
UAU/C (Tyr) codons were highly expressed – whereas
isoacceptors pairing to leucine codons exhibited lower
abundance in all models evaluated (Fig. 2). Globally,
tRNA fractions correlated among the tested models
(Additional file 1 Figure S2a), but for some tRNA isoac-
ceptor families (i.e. a family comprises all tRNA isoac-
ceptors carrying the same amino acid), the proportion
among the isoacceptors varied (Fig. 2). For example, in
all cells within the Thr-tRNA family – except HEK293 –
the isoacceptor with the highest concentration reads
ACU/C/G, whereas the lowest one pairs to the ACG-
codon. In HEK293, the tRNA reading ACA (Thr) was
the most highly expressed within this family (Fig. 2).
tRNAsGlu and tRNAsArg displayed larger fluctuations in
the proportion between isoacceptors within different
model systems.
Over the time course of iPSC differentiation to an air-
way organoid phenotype, overall abundance and distri-
bution of tRNAs remained relatively constant
(Additional file 1 Figure S2b). Fractions of high- or low-
abundance tRNAs mildly decreased or increased, re-
spectively (Additional file 1 Figure S2b), although those
changes did not reach statistical significance. Organoids
and FRT cells exhibited the lowest correlation to the
other models (Additional file 1 Figure S2a). On a global
scale, the three model cell lines, HEK293, HeLa and
CFBE41o−, were most similar to each other (Additional
file 1 Figure S2a), with HEK293 cells being the most di-
vergent (Fig. 2). It should be noted that modifications of
these cells for propagation in laboratory conditions
might alter their tissue-specific expression, i.e. deviation
from the ancestral tissue may be difficult to assess. In
addition, karyotypes of both HeLa and HEK293 are
largely divergent from a human cell line, due to viral
immortalization of HEK293 and natural integration of
the human papilloma virus in the HeLa model.
To further assess the influence of different tRNA con-
centrations on velocity of translation for each codon,
tRNAs reading more than one codon were divided
among cognate codons using the corresponding genomic
codon frequencies. The variation of translational speed
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for some codons was very large (e.g. GCG, CUA, CAU),
while some were equivalent regardless of the model be-
ing tested (e.g. GAC, GAU, AGG) (Additional file 1:
Figure S3). Next, we calculated differences in tRNA frac-
tion per codon in pairwise fashion. Codons falling in the
upper and lower quantiles are marked (Fig. 3). Among
the latter cohort, Ala-GCG was the most extreme (fre-
quent) outlier and would be expected to have the stron-
gest fluctuations in translational velocity among the
tested models.
Computing translation velocity
Codon frequencies, or codon adaptation index (CAI)
[47], are often used for gauging translation speed as they
can be easily inferred from genomic information and re-
flect core algorithms used to compute translation profile
[48, 49]. The underlying assumption of these measures
is that codon usage of highly expressed genes mirrors
cellular tRNA pools. Although this correlation has been
observed in prokaryotes and unicellular eukaryotes, it
has not been reproduced in higher eukaryotes [22, 50].
An alternative metric that captures both codon fre-
quency bias and tRNA abundance is the tRNA adapta-
tion index (tAI), which applies copy number of tRNA
genes and assumes correlation with tRNA abundance
[51–53]. This approach also poses limitations based on
discovery of tissue-specific variation in expression from
tRNA genes, and consequently, in tRNA abundance
among human tissues despite identical genetic informa-
tion (i.e. tRNA copy number or genomic codon usage
[46]). To capture differences in tRNA expression level in
multicellular eukaryotes, we developed a RiboTempo al-
gorithm that uses tRNA concentrations to compute
translation speed for each codon [54, 55]. Codons
Fig. 2 tRNAs exhibit similar concentration patterns among tested models. Values from comparative tRNA microarrays were converted into absolute
concentrations using comparative arrays versus HeLa, and represented for each codon as a fraction of total tRNA. Data are presented as a representative array
± SD between biological replicates (n= 4 for HEK293; n= 3 for CFBE41o−, FRT and HeLa; n= 2 for organoids, HNE and HBE; for iPSCs (zero time point) n= 12
of the array blocks). tRNA isoacceptors are depicted with their cognate codon and the corresponding amino acid; Meti, initiator tRNAMet. The tRNAomes of
HeLa and CBFE41o− cells are from [22]
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pairing to low-abundance tRNAs represent slow codons,
while those read by abundant tRNA species (Fig. 1) are
rapidly translated codons. The average rate of translation
along the entire transcript is computed by smoothing sin-
gle codon values with a sliding window representing the
size of mRNA covered by a translating ribosome [54].
Predicting the impact of synonymous SNVs on translation
rate
Within a single model, tRNAs varied in abundance by
an order of magnitude, and certain synonymous codons
exhibited several-fold differences (Fig. 2). Using tRNA
fractions per codon (i.e., with abundance of each tRNA
represented as a fraction of the total tRNAome for each
cell or tissue), we computed translation profiles for the
CFTR transcript based on a RiboTempo algorithm [54]
and observed non-uniform velocity (Fig. 4a). In this rep-
resentation, valleys correspond to slowly-translated re-
gions and peaks to rapidly-translated segments. Overall,
the CFTR translation profile was similar among models,
although subtle differences were noted in specific
regions (e.g. discrete positions in the R-domain and
membrane-spanning domains (MSDs) 1 and 2 were
translated more rapidly in some CF cell models, Fig. 4a).
In two regions – between codons 500–570 in
nucleotide-binding domain 1 (NBD1) and at the begin-
ning of NBD2 – we noted alterations of the local speed
of translation between models (Fig. 4a). Since translation
kinetics tunes synthesis at critical nodes of the CFTR
co-translational folding landscape [56], it is likely that
local alterations in the speed of translation may impact
biogenesis and yields of active protein in certain CF
models.
Our earlier observations in CFBE41o− cells indicate
that the synonymous c.2562 T > G SNP (Fig. 4a) modifies
local speed at Thr854 by introducing a codon (ACG)
that pairs to a very low-abundance tRNA compared to
the wild-type codon (ACT) with high-abundance tRNA
[22]. Hence, we next compared concentrations of the
tRNAsThr isoacceptor family members of each model to
those present in CFBE41o− (Fig. 4b). Since the concen-
tration of both tRNAsThr pairing to ACU/C/G and ACG,
Fig. 3 Ribosome occupancy at specific codons varies between models. Boxplots are shown describing pairwise differences in computed ribosome
occupancy for each codon between two models. For iPSCs, only the zero time point was considered. Codons with differences in the upper and lower
quantiles are designated with their identities. Codons found repeatedly in over ten combinations are color-coded
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respectively, is 1 in FRT, HBE, HeLa and iPSC (Fig. 3b),
or equal to these in CFBE41o−, it would be expected that
the c.2562 T > G SNP would have the same effect in
these models. In organoids, tRNAThr pairing to ACG is
much lower than in CFBE41o− cells, and consequently,
the predicted effect on translation velocity would be
even stronger (Fig. 4b). In contrast, both tRNAsThr
pairing to ACU/C/G and ACG codons are lower in HNE
than CFBE41o− cells. Between these two tRNAs, how-
ever, Thr-tRNACGU that reads ACG codon is diminished,
such that the effect of the synonymous c.2562 T > G
SNP would be still detected, although significantly less
pronounced. In HEK293 cells, concentrations of both
tRNAs pairing to wild-type ACT and mutant ACG co-
dons deviate in a direction opposite from those in
CFBE41o− cells (Fig. 3b), which is in line with our earlier
experimental observation that the synonymous c.2562
T > G SNP does not impact CFTR expression level and
function in HEK293 [22]. It should be noted that the
tRNAThrAGU pairing to ACU/C/G codons has an A nu-
cleotide at position 34 in the anticodon loop. An A34 at
this position is often deaminated to inosine [57], which
expands the coding capacity to pair with U/C/A (and
likely G) at the third nucleotide of codons [58]. Yet,
modifications of this sort in the human tRNAThr family
are not known (Modomics - tRNA modification data
base, http://modomics.genesilico.pl/), and it is therefore
unclear whether Thr-tRNAAGU would read an ACG
codon. Furthermore, the presence of A34 is advanta-
geous as a means to pair with fully degenerate
Fig. 4 CFTR translation is predicted to occur via non-uniform velocity, with synonymous mutations locally governing the rate of synthesis. a Computed
translation rate of CFTR for various tested cell or tissue models. The gray area marks the 10th–90th percentile to emphasize slow and rapidly translated
regions. Single CFTR domains are designated as color-coded bars at the top of the sequence: membrane-spanning domains 1 and 2 (MSD1, MSD2) (blue);
nucleotide-binding domains 1 and 2 (NBD1, NBD2) (blue); regulatory (R)-domain (red). sSNPs with prevalence higher than 1% in CFTR are marked with (●),
and the nucleotide exchange at the corresponding position is designated using the scheme: wild-type nucleotide, position, mutated nucleotide. b-d tRNA
concentration within the tRNAThr (b), tRNAGlu (c) and tRNAPro (d) families compared to those present in CFBE41o− cells. The synonymous SNP-induced
codon is designated in red. For iPSCs, only the zero time point was reported in all panels. tRNA isoacceptors are depicted with their cognate codon and
the corresponding amino acid
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synonymous codons by establishing a single tRNA that
reads all four codons, except when tRNAs dedicated to
some of the synonymous codons of interest are present
[59], implying that Thr-tRNAAGU may not pair to an
ACG codon which has its own isoacceptor.
Similar to c.2562 T > G, two additional synonymous
SNPs (c.1584G > A and c.3870A > G) reduced expression
of mature CFTR protein in CFBE41o− cells [22]. To
determine whether these sSNPs alter local translation
speed at each respective codon, we compared concentra-
tions of their cognate tRNAs in different models. The
synonymous c.1584G > A SNP, which is located in NBD1
(Fig. 4a), exchanges GAG to the GAA codon and is of
considerable interest with regard to the concentration of
the tRNA isoacceptor. This particular synonymous SNP
would be expected to increase local speed of translation
at the affected codon, with concentrations of cognate
tRNAs that differ by 2-fold in CFBE41o− cells (Fig. 2). In
all other models, the concentration difference between
tRNAs is substantial (e.g. the tRNA reading GAA/G is
much higher and the tRNA pairing to GAA is much
lower than in CFBE41o− cells, except for organoids);
thus, the effect of the G1584A synonymous SNP would
be even stronger than observed in CFBE41o− (Fig. 4c).
The synonymous c.3870A > G SNP (Fig. 4a) introduces
changes at the Pro1290 codon, but modifications in local
translation rate could not be computed due to high se-
quence similarity of the tRNAPro isoacceptors – which
are not unambiguously distinguished by the arrays (Fig.
4d and Additional File, S1). Differences among the
tRNAsPro family in these models suggest that the effect
of the c.3870A > G synonymous SNP on translation vel-
ocity may differ, but the direction of speed alteration
with the synonymous SNP at the affected codon cannot
be predicted.
We next applied the approach to two other transcripts,
ADAMTS13 and blood coagulation factor IX (F9), for
which synonymous SNVs that change expression levels
and/or conformation and function of the encoded protein
have been experimentally identified [60, 61]. Similar to
CFTR (Fig. 4a), ADAMTS13 and F9 transcripts are pre-
dicted to be translated with non-uniform velocity (Fig. 5a,
b). Two synonymous mutations, c.1716A >G at a Thr
codon and c.2280A >G at a Gly codon, have been shown
to alter expression yields of ADAMTS13 in HeLa cells
[60]. The synonymous c.1716A >G SNV in ADAMTS13 is
reminiscent of c.2562 T >G in CFTR, since it exchanges a
Thr encoding codon (ACA) pairing to a more abundant
tRNAThr for a mutant ACG codon read by a low-
abundance tRNA (Fig. 2 and data on the absolute tRNA
concentration in HeLa published in [22]). This suggests
that the synonymous c.1716A >G SNV inverts translation
velocity at the Thr codon in ADAMTS13. In FRT, HBE,
CFBE41o− and iPSC, the concentration of both tRNAsThr
pairing to ACA and ACG, respectively, is 1 or equal to
those in HeLa (Fig. 5c). Thus, it would be expected that
the c.1761A >G SNV would have the same effect in these
models. On the other hand, in organoids, HNE and
HEK293 cells, tRNAsThr pairing to ACG and ACA exhibit
very different patterns of abundance compared to HeLa,
and the effect of the c.1716A >G SNV on translational
speed at the Thr codon in ADAMTS13 might not be
detected. The c.2280A >G SNV at a Gly codon in
ADAMTS13 exchanges GGA to GGG, both of which are
read by tRNAs with fairly similar concentrations in HeLa
(Fig. 2). Hence, the effect of this synonymous SNV might
not be linked to the speed of codon translation. However,
differences in the levels of both tRNAsGly in HBE cells
may potentially have an effect on the Gly codon velocity
(Fig. 5d).
In F9, the synonymous c.459G > A exchange at a Val
codon is clinically reported to result in mild haemophilia
B and diminished factor IX expression [61]. In HeLa
cells, tRNA pairing to the cognate GUG codon has
higher concentration (by ~ 50%) than tRNA reading the
mutant GUA codon (Fig. 2 and data on the absolute
tRNA concentration in HeLa published in [22]), suggest-
ing an effect of this synonymous SNV on velocity of
codon translation. The similarity in tRNA abundance
between HeLa, CFBE41o−, HBE and iPSC indicates a
similar phenotype in these cell models (Fig. 5e). In con-
trast, based on levels of tRNA expression, the effect
should be reverted in FRT cells and organoids, and
would not be detectable in HNE cells (Fig. 5e). Together,
our results suggest that for synonymous SNVs known to
alter protein folding and/or expression levels, tRNA con-
centration holds potential for gauging the effect of the
synonymous SNV on local codon speed and pro-
grammed velocity of translation. By comparing tRNA
abundance among model systems, cell lines in which the
effect would persist could be selected.
Discussion
Examples of tissue-specific effects on genetic variation
[21–23] intimately link SNVs to the concentration of
components that comprise translation machinery, and
more precisely, abundance of ready-to-translate tRNA
molecules [25, 26]. Our results demonstrate that tRNA
households for different model systems used in disease-
related research and drug discovery are globally similar,
although key variations among models may strongly im-
pact the effect of SNVs and consequently influence fold-
ing, maturation or gating of particular CFTR mutations.
Synonymous SNVs have been extensively employed as a
marker of neutral mutation rates and genomic evolution
[62]. In the past decade, several studies have challenged
this view and shown an effect of synonymous SNVs on
protein structure and function, mRNA stability and
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processivity, as well as cell fitness, survival and adapta-
tion (reviewed in [63–65]). Local changes in mRNA
structure can be estimated using predictive algorithms
(e.g. Vienna package of the RNAfold algorithm). In
addition, alterations of splicing signals can be assessed
with a recently developed algorithm that allows identifi-
cation without relying on conserved coding features
[66]. Our systematic evaluation of tRNAomes establishes
that synonymous SNVs can also alter programmed
translation patterns with tissue- and cell-specific conse-
quences – including information that can be used to
predict genotype-phenotype modifications due to syn-
onymous SNVs.
Characterizing the phenotypic impact of SNVs is a
central challenge in the field of functional genomics.
Currently, computational algorithms are used to predict
ramifications and relevance of both polymorphisms and
disease-associated variants. Software and reference tran-
script sets used for annotating variants in this manner
can have a large effect on the resulting annotation. Sev-
eral attempts have been undertaken to introduce
guidelines defining potential causality of SNVs and to es-
tablish gold standards by which to verify functionality
[67–69]. Despite these efforts, false-positive calls con-
cerning some variants are still commonly noted. Ultim-
ate proof for a functional effect requires experimental
evidence, which is limited by the paucity of global bio-
chemical and/or functional analyses that evaluate entire
proteomes. The approach described here holds potential
for determining genotype-phenotype association for syn-
onymous SNVs, which are among the most difficult to
evaluate and verify experimentally. Rigorous quantifica-
tion of tRNAomes provides a single measure of func-
tional importance for each SNV and can be used as a
criterion for determining candidacy with phenotypic
impact.
Conclusions
In summary, synonymous SNVs can alter local riboso-
mal speed at specific codons, since translation velocity is
modulated by abundance of cognate tRNAs. Synonym-
ous SNVs exhibiting large differences in concentration
Fig. 5 Predicted translation profiles for ADAMTS13 (a) and blood coagulation factor IX (F9) (b) transcripts computed with RiboTempo using the
tRNA concentration of HeLa cells. The gray area marks the 10th–90th percentile. The position of exemplified sSNVs is marked with (●) and
designated using the scheme: wild-type nucleotide, position, mutated nucleotide. c-e tRNA concentration within the tRNAThr (c), tRNAGly (d) and
tRNAVal (e) families compared to those present in HeLa cells, which are set to 1. The synonymous SNP-induced codon is designated in red. For
iPSCs, only the zero time point was reported in all panels. tRNA isoacceptors are depicted with their cognate codon and corresponding amino acid
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of cognate tRNAs reading at a mutant versus wild-type
codon are expected to affect both protein biogenesis and
function. Variable concentrations of tRNA isoacceptors
in different cell models allow determination of SNVs
most likely to be neutral in certain models. Hence, the
suitability of a model system for a specific purpose –
and in particular, for drug screening – should be se-
lected based on the responsible SNV.
Methods
Analyzed samples and culture techniques
HeLa cells (American Type Culture Collection (ATCC)
no. CRM-CCL-2), HEK 293 cells (ATCC no. CRL-1573)
and immortalized CFBE41o− cells (kind gifts of Karl
Kunzelmann, University of Regensburg, Germany and
Dieter Gruenert, University of California San Francisco,
USA) were maintained in Dulbecco’s modified Eagle’s
medium (DMEM; PAN Biotech) or Earle’s minimal es-
sential medium (MEM; Biochrom), supplemented with
10% fetal calf serum (FCS; PAN Biotech) and 2mML-
glutamine (Gibco). CF patient-derived primary HBE cells
from lung biopsies (patient 1, ΔF508/ΔF508; patient 2,
ΔF508/G551D) were kindly provided by Raymond
Frizzell and Matthew Glover (University of Pittsburgh,
Pittsburgh, USA). HBE cells were obtained and isolated
following informed patient consent (HSTB, University
Pittsburgh, IRB approval #0506140) from lung transplant
recipients at the Human Airway Cell Core of the Univer-
sity of Pittsburgh, cultivated on transwell filters at 37 °C
and 5% CO2, trypsinized, pelleted, stored in RNAlater
(Ambion), and shipped on dry ice. Each patient-derived
HBE and organoid sample was considered a single bio-
logical replicate.
Generation of parental FRT epithelia have been de-
scribed previously [70]. Cells were cultured in F12 Ham
Coon’s modified nutrient mixture (Sigma) supplemented
with 2.68 g NaHCO3, 850 μL 2 N HCl (pH 7.3) and 5%
FBS per liter.
Primary human nasal epithelia (HNE) were purchased
from the Research Development Program (RDP) Experi-
mental Models Core at Emory University. Cells were ac-
quired by nasal curettage through an Emory IRB approved
protocol (IRB#00,042,577) following consent obtained by
the Cystic Fibrosis Biospecimen Repository (CFBR). HNE
were harvested from non-CF (CFTRWT/WT) individuals –
codes NL124 (male) and NL117 (female) – processed,
then expanded using the F + Y reprogramming method on
irradiated 3 T3 cell feeder layers as previously described
[71, 72].
Rectal tissue specimens were obtained by means of a
suction biopsy device from CF patients (homozygous
F508del) as part of regular patient care, and from
healthy controls, following approval of the study proto-
col by the Medical Ethical Committee of the Erasmus
MC University Medical Center. The isolation of intes-
tinal crypts from intestinal biopsies and organoid culture
were performed as described in detail elsewhere [73, 74].
In brief, epithelial tissue sheets (crypts) were separated
from the underlying tissue layers using a Ca2+-chelating
solution. Isolated crypts were embedded in Matrigel (BD
Bioscience) and incubated in Wnt3a-, EGF-, Noggin and
R-Spo-containing cell culture medium (WENR) at 37 °C
to promote organoid formation. Culture medium
(WENR) was refreshed every 2–3 days and organoids
subcultured weekly. For analysis, organoid fractions
(equivalent to ~ 300,000 cells) were collected 7 days after
seeding in ice-cold advanced DMEM/F12 (Invitrogen).
Organoids were washed twice in advanced DMEM/F12
to remove remaining traces of Matrigel, then snap-
frozen in liquid nitrogen. Samples were stored at − 80 °C
until further processing.
Airway progenitor directed differentiation of iPSCs
was performed as previously described [41, 42] with
slight modifications of the protocol. Briefly, timing and
density was optimized leading to 3-day incubation dur-
ing a definitive endoderm (DE) step, followed by a 1:4
clump-based split (~ 50–200 cells). Cells were then
grown in CFKBRa until Nkx2.1 specification peaked at
day 13. Post Nkx2.1+ progenitor specification, culture
was again divided using a 1:4 clump-based split (~ 500–
1000 cells). Culturing was continued in CFK media until
day 21, which was the end point for this experiment.
Aliquots at day 0, 5, 10, 15 and 21 were flash frozen in
liquid nitrogen, and stored at − 80 °C until further pro-
cessing for total RNA isolation.
tRNA microarrays
Total RNA from cells or organoids was isolated using
the TRIzol-method according to manufacturer’s protocol
(Ambion). RNA integrity was assessed by 10%-denatur-
ing PAGE. To fully deacylate tRNAs, 5 μg of total RNA
was incubated for 45 min at 37 °C in 100 mM Tris-HCl
buffer (pH 9.0). Deacylated samples were purified by pre-
cipitation with ethanol and one volume 100 mM NaOAc
(pH 4.8), supplemented with 100 mM NaCl and glycogen
(20 mg/mL). For subsequent normalization of arrays,
each sample was spiked with three or four in-vitro tran-
scribed tRNAs (2 μM of each), which do not cross-
hybridize with human tRNA.
Fluorescently labeled RNA:DNA hairpin oligonucleo-
tides were ligated to deacylated tRNA samples using T4
DNA ligase (NEB) for 1 h at room temperature. HEK
were used as comparison and labeled with Atto647
oligonucleotides, whereas other samples were typically
labeled with Cy3-labeled oligonucleotides. Labeled
tRNAs were extracted using phenol/chloroform/isomy-
lalcohol (Roth) and precipitated with ethanol. Efficiency
of ligation was analyzed by 10%-denaturing PAGE, and
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comparison of fluorescent signals to total tRNA was vi-
sualized by staining with SYBR gold (Invitrogen).
1–2 μg of labeled tRNAs from analyzed samples and
HEK were simultaneously hybridized for 16 h at 60 °C
on a microarray chip containing 24 technical replicates
of each full-length tDNA. The detailed experimental
protocol [44] is available at protocols.io [doi:dx.doi.org/
10.17504/protocols.io.hetb3en].
Scanned microarray slides were analyzed using in-
house Python scripts. Briefly, median of the ratio of
Cy3/Atto647 signals was normalized to spiked samples
with ratio set to one. Similarity for each isoacceptor be-
tween each pair of two biological replicates was assessed
using variance analysis (Additional file 1: Figure S1), and
overall similarity between replicates determined by two-
sided Kolmogorov-Smirnov test. For individual models,
the biological replicate exhibiting lowest internal vari-
ation over all tRNA probes was selected as a representa-
tive example and depicted with mean standard deviation
for all probes. The latter was used to compute ribosome
occupancy, and as input for the RiboTempo algorithm.
Data analysis
Absolute tRNA concentration in HeLa [22] was used as
a baseline set to convert tRNA isoacceptor abundancies
from comparative microarrays into absolute units repre-
sented as a fraction of total tRNA (Fig. 1). For tRNA iso-
acceptors pairing to more than one codon, the fraction
per codon was determined using the corresponding
codon-usage index. Values for codons read by more than
one tRNA were summed. The fractions of all tRNAs for
one species were normalized to 100%.
Ribosome occupancy was computed as a reciprocal of
the tRNA concentration for each sense codon [55]. The
putative rate of translation along sequences was com-
puted with RiboTempo (https://www.chemie.uni-ham-
burg.de/institute/bc/arbeitsgruppen/ignatova/tools-and-
algorithms.html) using a harmonic mean function within
a sliding window of 30-codon width.
Data availability
tRNA microarray data for FRT, HBE, HNE, organoids
and iPSCs are provided as a source file in Additional file
2. tRNA microarray data for CFBE41o−; HEK293 and
HeLa cells, including sequences of tDNA probes used
for the arrays, have been deposited with the Gene Ex-
pression Omnibus (GEO) under accession number
GSE53991 [22].
Additional file
Additional file 1: Figure S1. Biological replicates of the comparative
tRNA microarrays are highly reproducible. a-e Data for HBE (a), organoids
(b), CFBE41o- (c), FRT (d) and HNE from a male (NL124) or female (NL117)
individual (e) are shown as fold-enrichment (gradient ruler at the bottom)
of tRNAs compared with HEK293 cells. Global reproducibility between
each two replicates was assessed by Kolmogorov-Smirnov test (for all
arrays p ≥ 0.9, i.e. very similar). The reproducibility for each tRNA probe
was assessed by variability analysis of each two replicates and is presented as
coefficient of variance. tRNA isoacceptors are depicted with their anticodon
and corresponding amino acid; Meti-CAU, initiator tRNAMet pairing to the
AUG codon. Figure S2. Correlation of tRNA abundance between tested
models. a Pairwise correlation of tRNA isoacceptor abundancies. For iPSCs,
only the zero time point was considered. R, Pearson correlation coefficient. b
Correlation of tRNA isoacceptor abundancies for iPCSs over the course of
differentiation. Stem cells at days 5, 10, 15 and 21 (gradient ruler) were
compared to non-differentiated cells at time zero. Figure S3. Standard
deviations of computed ribosome occupancies per codon among
models. In these calculations, only the zero time point was considered
for iPSCs. (DOCX 1932 kb)
Additional file 2: Source data tRNA microarrays. (XLSX 18 kb)
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